Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 09/29 10:00:31 pm
117.27 USD   -1.78%
04:37p DOW MOVERS : Mrk, cat
09/28 GLOBAL DRUG ELU : BOSTON SCIENTIFIC, JOHNSON and JOHNSON, ABBOTT LAB..
09/28 3D SIGNATURES : TSXV-listed 3D Signatures Names Jason Flowerday as N..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Corrected: Citi's pay rejection a wake-up call to boards

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/20/2012 | 09:07pm CEST

Institutional investors are increasingly pressing boards to rein in outsized executive pay, and after Citigroup (>> Citigroup Inc.) shareholders rejected a compensation plan on Tuesday, more directors may start listening.

Institutional investors are increasingly pressing boards to rein in outsized executive pay, and after Citigroup (>> Citigroup Inc.) shareholders rejected a compensation plan on Tuesday, more directors may start listening.

Shareholders on Tuesday handed Citigroup an embarrassing no confidence vote on a $15 million pay package for its Chief Executive Vikram Pandit. About 55 percent of shareholders rejected a plan to bring Pandit's pay back close to levels before the global financial crisis.

The no vote signals dissatisfaction with lucrative pay at companies that have not lived up to industry standards, governance experts said.

"As we struggle to come out of the recession, CEO packages have continued to increase at a rate that is much greater than the rate of economic performance of these companies," said James Post, a management professor at Boston University.

That has become a flashpoint in a country that was already outraged over pay inequality, and many boards are paying attention, investors said.

"The culture of this country has shifted on this issue," said Eric Veiel, portfolio manager for T. Rowe Price's financial services fund.

Boards are following the public's lead and trends like last fall's "Occupy Wall Street" movement against wealth disparity, he said.

TOUGHER TEST IN 2012

Citigroup's shares are up 33 percent this year, but the bank still faces challenges, including failing to win approval from regulators for a dividend increase or stock buyback. On Monday it posted a 2 percent drop in net income for the first quarter as it struggled to boost profits in a sluggish economy.

The vote on Pandit's pay is nonbinding, but governance experts said it would be difficult for the board to ignore it.

"Everywhere on the political and social side we see a country that is terribly divided over compensation and economic inequality," said Post of Boston University. "CEOs are the poster children for this."

Shareholders won the right to vote on executive pay at most public companies with the 2010 Dodd-Frank act, though many observers were skeptical that the advisory votes would make much difference.

Average CEO pay fell during the recession, but surged in 2010 as a recovering stock market triggered more bonus awards. Preliminary data from Meridian Compensation Partners suggests pay rose more modestly in 2011.

While few companies had their pay plans rejected last year, they could face a tougher test in 2012, partly because institutional investors have had more time to fully prepare for the votes.

"It's not a matter of share owners sitting on their hands," said Anne Simpson, director of corporate governance for the California Public Employees' Retirement System, or Calpers. "Last year all of the big share owners like Calpers were working out their framework for analyzing these proposals."

Last year, only 41 companies failed to get majority support for their pay out of an estimated 2700 companies in the Russell 3000 index that held votes.

But roughly 160 additional companies got just 70 percent or less support for the measures, according to governance research firms that track the votes. Those companies could face more shareholder resistance if they did not reform their pay packages.

Some large asset managers lately have taken a more aggressive stand on pay questions and have been backing shareholder resolutions asking for pay changes.

Fidelity Investments of Boston supported 21 percent of shareholder resolutions related to pay last year, up from 8 percent in 2010 and 0.3 percent in 2009, according to Fund Votes, a Vancouver research firm.

Fidelity executives did not immediately respond to questions.

CALPERS GETS BOARDS ATTENTION

Calpers voted against 201 plans last year and has found those companies' boards responsive to its concerns, said Todd Mattley, head of proxy voting at the pension fund.

Companies that got over 50 percent no votes "are doing their homework and due diligence and really trying to figure out what was wrong with their compensation packages," he said.

Not everyone expects big changes as a result of the say-on-pay votes.

CEO pay has shot higher because board compensation committees base it largely on peer comparisons and usually aim to be a at least a bit above average, which means pay gets benchmarked to other companies' high levels, governance experts said.

"It's the overuse of peer groups that's created an upward spiral in pay," said Charles Elson, director of the Center for Corporate Governance at the University of Delaware. "Even the best compensation committee that uses a peer group is going to create problems."

But last year's rejections and scrutiny seem to have prompted some companies to change their plans before having them publicly reviewed in this year's votes, said Amy Borrus, deputy director of the Council of Institutional Investors, whose members have more than $3 trillion under management.

Johnson & Johnson (>> Johnson & Johnson), for example, modified its compensation plans after nearly 40 percent of votes were cast against it last year. The company replaced some cash incentives that had been in place more than 60 years with stock awards tied to sales, earnings and shareholder returns. A spokesman for the company declined to comment.

(Corrects school name to Boston University from Harvard University in paragraphs 4 and 10 in April 18 story.)

(Additional reporting by David Henry; Editing by Patricia Kranz and Leslie Gevirtz)

By Dena Aubin and Ross Kerber

Stocks treated in this article : Citigroup Inc., Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05:30p JOHNSON & JOHNSON : Advances Commitment to Improve Global Health and Well-Being
05:17p JOHNSON & JOHNSON : Recent Findings from Johnson & Johnson Has Provided New Info..
04:37p DOW MOVERS : Mrk, cat
09/28 GLOBAL DRUG ELUTING STENTS (DES) MAR : BOSTON SCIENTIFIC, JOHNSON and JOHNSON, A..
09/28 3D SIGNATURES : TSXV-listed 3D Signatures Names Jason Flowerday as New CEO
09/27 JOHNSON & JOHNSON : Two US companies eye Seagate land in Batu Kawan
09/26 JOHNSON & JOHNSON : FDA Approves STELARA® (Ustekinumab) for Treatment of Adults ..
09/26 JOHNSON & JOHNSON : Research finds talc doesn't cause cancer; juries disagree
09/25 JOHNSON & JOHNSON : The Philadelphia Inquirer Kellie Patrick Gates column
09/25 JOHNSON & JOHNSON : Dennis W. Weaver
More news
Sector news : Pharmaceuticals - NEC
02:40pDJGLAXOSMITHKLINE : Appoints New Consumer Healthcare Chief
10:26aDJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:43a PHILIP MORRIS INTERNATIONAL : Great Dividend Income Company With Inelastic Produ..
09/28 Obalon Therapeutics IPO May Inflate Company Prospects
09/28 VALUATION IS A MEASUREMENT OF SOUNDN : Part 1
09/28 BIOTECH FORUM DAILY DIGEST : Notable Trial Failures; NASH Continues To Be Tough ..
09/28 JOHNSON & JOHNSON : Buying The Dips Beats The Drips - Timing Not An Issue
Advertisement
Financials ($)
Sales 2016 72 075 M
EBIT 2016 21 925 M
Net income 2016 16 508 M
Finance 2016 14 428 M
Yield 2016 2,63%
P/E ratio 2016 20,33
P/E ratio 2017 17,91
EV / Sales 2016 4,33x
EV / Sales 2017 4,06x
Capitalization 326 636 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 6,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON16.23%326 636
ROCHE HOLDING LTD.-12.41%217 190
NOVARTIS AG-10.14%212 589
PFIZER INC.5.30%206 172
MERCK & CO., INC.19.84%175 038
GLAXOSMITHKLINE PLC20.54%105 036
More Results